Fintel reports that on April 2, 2025, HC Wainwright & Co. upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) ...

Highlights,Cabaletta Bio receives a favorable evaluation from HC Wainwright.,An institutional review brings renewed focus to ...

CG Oncology (NASDAQ:CGON – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright ...

Genelux (NASDAQ:GNLX – Get Free Report)‘s stock had its “buy” rating restated by HC Wainwright in a note issued to investors ...

H.C. Wainwright analyst Ed Arce maintained a Hold rating on Galectin Therapeutics (GALT – Research Report) today. The company’s shares closed ...

H.C. Wainwright analyst Kevin Dede maintained a Hold rating on Mawson Infrastructure Group (MIGI – Research Report) today. The company’s shares ...

Fintel reports that on March 31, 2025, HC Wainwright & Co. initiated coverage of Virax Biolabs Group (NasdaqCM:VRAX) with a ...

Highlights,Vanda Pharmaceuticals posts improved earnings, surpassing market expectations.,Company executives increase stock ...

GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural ...

Virax Biolabs' T-cell testing platform targets post-viral syndromes like Long COVID. HC Wainwright sees a major market opportunity, setting a $3 price target.

Despite a major shift toward Bitcoin losing 10% of its value since the start of the year.